Current Studies:
-
Description: A study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers.
Qualifications:
Participants who are healthy as determined by medical evaluation including medical history
Born at full term of pregnancy (≥ 37 weeks)
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine.
Qualifications:
Participants between the ages of 6 to <17 of age.
Must have a history and diagnosis of migraine with or without aura
Have a history of migraine attacks for more than 6 months
Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening
Duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours
Participant must be able to swallow a tablet
For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening
Participants must weigh at least 15 kilograms (kg)
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine.
Qualifications:
Participants must have completed the Pediatric & Adolescent Migraine Study I.
Participants must weigh at least 15 kilograms (kg)
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: The main purpose of this study is to evaluate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine.
Qualifications:
Participants between the ages of 6 to 17 years of age.
Have a diagnosis of migraine with or without aura with a history of migraine headaches of at least 6 months prior to screening.
Have a history of 4-14 headache days per month, of which at least 4 are migraine headache days, and with at least 2 migraine attacks per month
Have received age-appropriate immunizations.
Are males and females who agree to abide by the reproductive and contraceptive requirements.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age.
Qualifications:
Participants between the ages of 12 to 17 years of age.
Have a diagnosis of chronic migraine with a history of at least 3 months prior to screening.
Have a frequency of at least 15 headache days during prospective baseline period of which at least 8 must have the features of migraine.
Have at least 1 headache-free day per 30-day period during prospective baseline period.
Have received age-appropriate immunizations.
Are males and females who agree to abide by the reproductive and contraceptive requirements.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
-
Description: A study to evaluate the safety and efficacy of various investigational interventions for Chronic Weight Management in Adult Participants with Obesity or Overweight.
Qualifications:
Participants age between 18 to 75 years of age.
BMI ≥30 kilograms per square meter (kg/m²) or Have a BMI ≥27 kg/m² and <30 kg/m² with at least one of the following weight-related comorbidities:
hypertension: on blood pressure (BP)-lowering medication.
dyslipidemia: on lipid-lowering medication
cardiovascular (CV) disease: for example, ischemic CV disease, New York Heart Association (NYHA) Functional Classification -Class 1 or II Heart Failure
obstructive sleep apnea
Have had a stable body weight without many changes within the last 3 months.
Are males and females who agree to abide by the reproductive and contraceptive requirements
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
Upcoming Studies:
-
More information coming soon…
Other Studies:
BabyCove Vaccine Study
Description: A study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants.
Qualifications:
Healthy Babies between the ages of 2 months old to less than <6 months of age
Participant was born at ≥37 weeks gestation (Part 1) or ≥34 weeks gestation (Part 2)
Must have not received any SARS-Cov-2 Vaccines
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
Pediatric MMR Vaccine Study
Description: A study to evaluate the immunogenicity and safety of a measles, mumps, rubella, varicella vaccine compared with ProQuad, administered in healthy children 4 to 6 years of age.
Qualifications:
Healthy participants age between 4 to 6 years of age (from 4-year birthday until the day before the 7-year birthday)
Participants who previously received a first dose of varicella-containing vaccine from 12 months to <24 months of age.
Participants who previously received a single dose of measles-, mumps-, rubella- containing vaccine from 12 months to <24 months of age.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
Major Depressive Disorder I Study
Description: A study to evaluate the efficacy and safety of Bupropion Hydrobromide in Adolescents and Children with Major Depressive Disorder.
Qualifications:
Participants who are aged ≥7 to <18 years.
Meet diagnostic criteria for MDD
Have current depressive episode of at least 4 weeks in duration as noted in the participant's history
Are on stable doses for allowed medication for a period of 30 days prior to visit 2 and not expected to change during the study and follow-up periods.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.
Major Depressive Disorder II Study (Extension)
Description: A study to evaluate the safety and tolerability of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
Qualifications:
Participants who successfully completed the Major Depressive Disorder I study.
Are males and females of childbearing potential who agree to use adequate contraception methods during study.
Meet diagnostic criteria for MDD
Are on stable doses for allowed medication for a period of 30 days prior to the Transition Visit and not expected to change during the study and follow-up periods.
Participants will also be compensated for time, travel, and participation. This gives participants the opportunity to receive study-related treatment and medication at no cost.